Skip to content

Dr. Steven Shnyder,
Associate Professor

Information about Dr. Steven Shnyder at the University of Bradford.

School of Pharmacy & Medical Sciences
(Faculty of Life Sciences)
+44 1274 235898
Photo of Dr. Steven Shnyder


Dr Steve Shnyder is a Senior Lecturer in Cancer Biology at the ICT. He has thirty-five years’ experience as a research scientist: 30 years post-doctoral, 18 months in a start-up pharma, with the past 24 years in a preclinical cancer pharmacology environment at Bradford. He has over 30 years’ experience of working with small mammals, mainly in the preclinical cancer pharmacology field. In his current position he is a Home Office Project and Personal Licence holder and is involved in the management and practical execution of Research and Knowledge Transfer in vivo and in vitro studies carried out at the ICT, working with both UK-based and international clients. His team has contributed to the screening packages of several novel anti-cancer compounds which have subsequently progressed to clinical trials and beyond, using both cell-based and in vivo technologies. He is an author on 80+ journal articles and numerous conference publications as well as four book chapters on in vivo methodology. In addition he has significant experience in the areas of histopathology, biochemistry and cell biology. He line manages a Research Associate whose focus is in vivo studies, and a Research Technician whose focus is in vitro screening. He is a strong proponent of 3Rs philosophy, always striving to apply the 3Rs to all the work he does, and he has been a co-investigator on 2 project grants and a studentship specifically aimed at improving methodology in preclinical cancer pharmacology from a 3Rs standpoint. Aside from this, his main research interests are focused around identifying mechanisms of drug resistance in colorectal cancer.


Characterisation of the reticuloplasmins as anticancer drug targets. Pharmacology of vascular disrupting agents. Development of 3Rs methodologies. Exploitation of the fluorescent properties of anti-cancer therapeutics for utilisation in assessment of pharmacodynamic and pharmacokinetic end-points. Evaluation of the drugability of the tumour cell glycocalyx. Research Team Patricia Cooper, Experimental Officer Gary Lawson, Research Technician Marcella Sini, YCR Programme Grant Postdoctoral Researcher (with L Patterson, P Loadman, R Falconer & K Pors)

Professional activities

Information about education, employment and areas of particular interest for Dr. Steven Shnyder is as follows:


  • London - PhD
  • Bradford - BSc
  • Bradford - MPhil


There are 85 publications involving or that are attributed to Dr. Steven Shnyder. They are listed as:

  • book chapter (1)
  • conference publication (2)
  • peer reviewed journal (78)
  • reviews (4)

Book Chapter

Dr. Steven Shnyder has 1 publication(s) listed under book chapter.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Oncology Activity 2015 Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition 4157 - 4200 Gill J.;Shnyder S. 9783319053929 Springer 10.1007/978-3-319-05392-9_113

Conference Publication

Dr. Steven Shnyder has 2 publication(s) listed under conference publication.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
A non-invasive 2D digital imaging method for detection of surface lesions using machine learning 2017 Proceedings - 2017 International Conference on Cyberworlds, CW 2017 - in cooperation with: Eurographics Association International Federation for Information Processing ACM SIGGRAPH Proceedings - 2017 International Conference on Cyberworlds, CW 2017 - in cooperation with: Eurographics Association International Federation for Information Processing ACM SIGGRAPH 2017-January 166 - 169 Hussain N.;Cooper P.;Shnyder S.;Ugail H.;Bukar A.;Connah D. 9781538620892 10.1109/CW.2017.39
2017 A Non-invasive 2D Digital Imaging Method for Detection of Surface Lesions Using Machine Learning A Non-invasive 2D Digital Imaging Method for Detection of Surface Lesions Using Machine Learning Hussain, Nosheen; Cooper, Patricia A.; Shnyder, Steven D.; Ugail, Hassan; Bukar, Ali M.; Connah, David

Peer Reviewed Journal

Dr. Steven Shnyder has 78 publication(s) listed under peer reviewed journal.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Secretory phospholipase A2 as a tumor specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids 2004 Gill, Jason H.; Bibby, Michael C.; Jensen, S.S.; Shnyder, Steven D.
A Proteomic Investigation to Discover Candidate Proteins Involved in Novel Mechanisms of 5-Fluorouracil Resistance in Colorectal Cancer 2024 Cells 13 Mario Ortega Duran, Sadr ul Shaheed , Christopher W. Sutton and Steven D. Shnyder MDPI 10.3390/cells13040342
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds 2021 BIOORGANIC & MEDICINAL CHEMISTRY 40 Natalia Ortuzar, Kersti Karu, Daniela Presa, Goreti R. Morais, Helen M. Sheldrake, Steve D. Shnyder, Francis M. Barnieh, Paul M. Loadman, Laurence H. Patterson, Klaus Pors, Mark Searcey 10.1016/j.bmc.2021.116167
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy 2023 Cancers 15 Mark Sutherland, Andrew Gordon, Fatemah OFO Al-Shammari, Adam Throup, Amy Cilia La Corte, Helen Philippou, Steven D Shnyder, Laurence H Patterson, Helen M Sheldrake
Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis and Cancer 2022 Frontiers in Pharmacology 13 Abacha, YZ; Donkor Forkuo, A; Gbedema, SY; Mittal, N; Ottilie, S; Rocamora, F; Winzeler, EA; van Schalkwyk, DA; Kelly, JM; Taylor, MC; Reader, J; Birkholtz, L-M; Lisgarten, DR; Cockcroft, JK; Lisgarten, JN; Palmer, RA; Talbert, RC; Shnyder, SD, Wright, CW doi: 10.3389/fphar.2022.875647
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. 2021 Scientific Reports 11 Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; 2045-2322 10.1038/s41598-021-98217-z
The role of MT1-MMP in the progression and metastasis of osteosarcoma 2022 Journal of Cancer Metastasis and Treatment 9 Spencer, H.L.M.; Shnyder, S.D.; Loadman, P.M.; Falconer, R.A. DOI:10.20517/2394-4722.2021.174
An assay for quantitative analysis of polysialic acid expression in cancer cells 2021 Carbohydrate Polymers 259 Guo, X.; Elkashef, S.M.; Patel, A.; Ribeiro Morais, G.; Shnyder S.D.; Loadman, P.M.; Patterson, L.H.; Falconer, R.A. 10.1016/j.carbpol.2021.117741
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. 2021 Bioorganic and Medicinal Chemistry 40 Ortuzar N;Karu K;Presa D;Morais GR;Sheldrake HM;Shnyder SD;Barnieh FM;Loadman PM;Patterson LH;Pors K;Searcey M; 1464-3391 10.1016/j.bmc.2021.116167
Application of Small Molecule FPR1 Antagonists in the Treatment of Cancers 2020 Scientific Reports na Djevdet S. Ahmet, Haneen A. Basheer, Anwar Salem, Di Lu, Amin Aghamohammadi, Patrick Weyerhäuser, Andrea Bordiga, Juman Almeniawi, Sabah Rashid, Patricia A. Cooper, Steven D. Shnyder, Victoria Vinader, and Kamyar Afarinkia Nature
An efficient assay for identification and quantitative evaluation of potential polysialyltransferase inhibitors. 2020 ANALYST (PRINT) 145 4512 - 4521 Guo X; Malcolm J.R.; Ali M.M.; Ribeiro Morais G; Shnyder S.D.; Loadman P.M.; Patterson L.H.; Falconer R.A. 1364-5528 10.1039/d0an00721h
Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex 2020 ChemMedChem Soldevila-Barreda J.J.;Azmanova M.;Pitto-Barry A.;Cooper P.A.;Shnyder S.D.;Barry N.P.E. 1860-7179 10.1002/cmdc.202000096
Use of the hollow fibre assay for studies of tumor neovasculature. 2009 Methods in molecular biology (Clifton, N.J.) 467 331 - 342 Shnyder S. 1064-3745 10.1007/978-1-59745-241-0_21
Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer 2019 O'Flaherty, L.; Shnyder, Steven D.; Cooper, Patricia A.; Cross, S.J.; Wakefield, J.G.; Pardo, O.E.; Seckl, M.J.; Tavare, J.M.
A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations used in Ghana 2008 Natural product communications Bayor, M.T.;Ayim, J.S.K.;Marston, G.;Phillips, R.M.;Shnyder, S.D.;Wheelhouse, R.T.;Wright, C.W.;
Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity 2008 Journal of Immunology 180 8176 - 8183 Krippner-Heidenreich A.;Grunwald I.;Zimmermann G.;Kühnle M.;Gerspach J.;Sterns T.;Shnyder S.;Gill J.;Männel D.;Pfizenmaier K.;Scheurich P. 0022-1767 10.4049/jimmunol.180.12.8176
NCAM polysialylation during adherence transitions: Live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7 2013 Cytometry Part A 83 659 - 671 Smith P.;Furon E.;Wiltshire M.;Chappell S.;Patterson L.;Shnyder S.;Falconer R.;Errington R. 1552-4922 10.1002/cyto.a.22306
Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex 2011 MedChemComm 2 666 - 668 Shnyder S.;Fu Y.;Habtemariam A.;Van Rijt S.;Cooper P.;Loadman P.;Sadler P. 2040-2503 10.1039/c1md00075f
Synthesis and biological evaluation of colchicine B-ring analogues tethered with halogenated benzyl moieties 2012 Journal of Medicinal Chemistry 55 11062 - 11066 Cosentino L.;Redondo-Horcajo M.;Zhao Y.;Santos A.;Chowdury K.;Vinader V.;Abdallah Q.;Abdel-Rahman H.;Fournier-Dit-Chabert J.;Shnyder S.;Loadman P.;Fang W.;Díaz J.;Barasoain I.;Burns P.;Pors K. 0022-2623 10.1021/jm301151t
Use of the hollow fiber assay for the evaluation of DNA damaging agents 2011 Journal of Pharmacological and Toxicological Methods 64 226 - 232 Veiga J.;Cooper P.;Pors K.;Patterson L.;Bibby M.;Shnyder S. 1056-8719 10.1016/j.vascn.2011.04.006
Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model 2003 Anticancer Research 23 1619 - 1623 Shnyder S.;Cooper P.;Pettit G.;Lippert J.;Bibby M. 0250-7005
An agarose spot chemotaxis assay for chemokine receptor antagonists 2011 Journal of Pharmacological and Toxicological Methods 64 213 - 216 Vinader V.;Al-Saraireh Y.;Wiggins H.;Rappoport J.;Shnyder S.;Patterson L.;Afarinkia K. 1056-8719 10.1016/j.vascn.2011.01.004
Secretory phospholipase A2as tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids 2004 Molecular Cancer Therapeutics 3 1451 - 1458 Jensen S.;Andresen T.;Davidsen J.;Høyrup P.;Shnyder S.;Bibby M.;Gill J.;Jørgensen K. 1535-7163
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases 2010 Cancer Research 70 6902 - 6912 Atkinson J.;Falconer R.;Edwards D.;Pennington C.;Siller C.;Shnyder S.;Bibby M.;Patterson L.;Loadman P.;Gill J. 0008-5472 10.1158/0008-5472.CAN-10-1440
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts 2009 Molecular Cancer Therapeutics 8 3266 - 3275 Williams K.;Albertella M.;Fitzpatrick B.;Loadman P.;Shnyder S.;Chinje E.;Telfer B.;Dunk C.;Harris P.;Stratford I. 1535-7163 10.1158/1535-7163.MCT-09-0396
The hollow fibre model - Facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare 2006 International Journal of Oncology 29 1493 - 1499 Suggitt M.;Cooper P.;Shnyder S.;Bibby M. 1019-6439
Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates 2006 Journal of Medicinal Chemistry 49 5442 - 5461 Wells G.;Martin C.;Howard P.;Sands Z.;Laughton C.;Tiberghien A.;Woo C.;Masterson L.;Stephenson M.;Hartley J.;Jenkins T.;Shnyder S.;Loadman P.;Waring M.;Thurston D. 0022-2623 10.1021/jm051199z
Tubulin-binding dibenz[c,e]oxepines: Part 2.1Structural variation and biological evaluation as tumour vasculature disrupting agents 2017 Bioorganic and Medicinal Chemistry 25 1630 - 1642 Rossington S.;Hadfield J.;Shnyder S.;Wallace T.;Williams K. 0968-0896 10.1016/j.bmc.2017.01.027
Synthesis of cryptolepine analogues as potential bioreducible anticancer agents 2007 Bioorganic and Medicinal Chemistry 15 6353 - 6360 Seville S.;Phillips R.;Shnyder S.;Wright C. 0968-0896 10.1016/j.bmc.2007.06.062
Polysialyltransferase: A new target in metastatic cancer 2012 Current Cancer Drug Targets 12 925 - 939 Falconer R.;Errington R.;Shnyder S.;Smith P.;Patterson L. 1568-0096 10.2174/156800912803251225
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor 2010 Gene Therapy 17 1000 - 1010 Harvey T.;Burdon D.;Steele L.;Ingram N.;Hall G.;Selby P.;Vile R.;Cooper P.;Shnyder S.;Chester J. 0969-7128 10.1038/gt.2010.45
In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine 2002 European Journal of Cancer. Part A 38 194 - 204 Nicholson K.;Phillips R.;Shnyder S.;Bibby M. 0959-8049 10.1016/S0959-8049(01)00341-0
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature 2005 Anticancer Research 25 1889 - 1894 Shnyder S.;Hasan J.;Cooper P.;Pilarinou E.;Jubb E.;Jayson G.;Bibby M. 0250-7005
Reducing the cost of screening novel agents using the hollow fibre assay 2006 Anticancer Research 26 2049 - 2052 Shnyder S.;Cooper P.;Scally A.;Bibby M. 0250-7005
Vinflunine Pierre Fabre/Bristol-Myers Squibb 2004 IDrugs : the investigational drugs journal 7 851 - 859 Shnyder S. 1369-7056
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours 2002 Anticancer Research 22 707 - 711 Holwell S.;Cooper P.;Grosios K.;Lippert J.;Pettit G.;Shnyder S.;Bibby M. 0250-7005
Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation 2012 Bioorganic and Medicinal Chemistry Letters 22 7693 - 7696 Fournier-Dit-Chabert J.;Vinader V.;Santos A.;Redondo-Horcajo M.;Dreneau A.;Basak R.;Cosentino L.;Marston G.;Abdel-Rahman H.;Loadman P.;Shnyder S.;Díaz J.;Barasoain I.;Falconer R.;Pors K. 0960-894X 10.1016/j.bmcl.2012.09.104
Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in a human colon tumor model 2008 Journal of Natural Products 71 321 - 324 Shnyder S.;Cooper P.;Millington N.;Gill J.;Bibby M. 0163-3864 10.1021/np070477p
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo 2011 Cancer Gene Therapy 18 773 - 784 Harvey T.;Hennig I.;Shnyder S.;Cooper P.;Ingram N.;Hall G.;Selby P.;Chester J. 0929-1903 10.1038/cgt.2011.43
Vinflunine Potentiates the Activity of Cisplatin but Not 5-Fluorouracil in A Transplantable Murine Adenocarcinoma Model 2003 Anticancer Research 23 4815 - 4820 Shnyder S.;Cooper P.;Gyselinck N.;Hill B.;Double J.;Bibby M. 0250-7005
Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer 2008 Journal of Proteome Research 7 3364 - 3372 Shnyder S.;Mangum J.;Hubbard M. 1535-3893 10.1021/pr800126n
Organometallic osmium arene complexes with potent cancer cell cytotoxicity 2010 Journal of Medicinal Chemistry 53 8192 - 8196 Fu Y.;Habtemariam A.;Pizarro A.;Van Rijt S.;Healey D.;Cooper P.;Shnyder S.;Clarkson G.;Sadler P. 0022-2623 10.1021/jm100560f
Improved preparation and detection of cytochrome P450 isoforms using MS methods 2010 Proteomics 10 327 - 331 Sutton C.;Sutherland M.;Shnyder S.;Patterson L. 1615-9853 10.1002/pmic.200900489
Hypoxia modulates CCR7 expression in head and neck cancers 2018 Basheer, Haneen A.; Pakanavicius, E.; Cooper, Patricia A.; Shnyder, Steven D.; Martin, L.; Hunter, K.D.; Vinader, Victoria; Afarinkia, Kamyar
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate 2004 Kirwan, Ian G.; Loadman, Paul M.; Swaine, David J.; Anthoney, Alan; Pettit, G.R.; Lippert III, J.W.; Shnyder, Steven D.; Cooper, Patricia A.; Bibby, Michael C.
Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands 2017 Cancer Letters 397 Allison, Simon J.; Sadiq, Maria; Baronou, Efstathia; Cooper, Patricia A.; Dunnill, C.; Georgopoulos, N.T.; Latif, A.; Shepherd, S.L.; Shnyder, Steven D.; Stratford, I.J.; Wheelhouse, Richard T.; Willans, C.; Phillips, Roger M.
Agarose Spot as a Comparative Method for in situ Analysis of Simultaneous Chemotactic Responses to Multiple Chemokines 2017 Ahmed, Mohaned S.A.; Basheer, Haneen A.; Ayuso, J.M.; Ahmet, Djevdet; Mazzini, Marco; Patel, Roshan; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar
RGD-Binding Integrins in Head and Neck Cancers 2017 Ahmedah, H.T.; Patterson, Laurence H.; Shnyder, Steven D.; Sheldrake, Helen M.
Tubulin-binding dibenz[c,e]oxepines. Part 2. 1 Structural variation and biological evaluation as tumour vasculature disrupting agents 2017 Rossington, S.B.; Hadfield, J.A.; Shnyder, Steven D.; Wallace, T.W.; Williams, K.J.
Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells 2014 van Rijt, S.H.; Romero-Canelón, I.; Fu, Y.; Shnyder, Steven D.; Sadler, P.J.
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity 2013 Sheldrake, Helen M.; Travica, S.; Johansson, I.; Loadman, Paul M.; Sutherland, Mark H.; Elsalem, Lina M.I.; Illingworth, Nicola A.; Cresswell, Alexander J.; Reuillon, Tristan; Shnyder, Steven D.; Mkrtchian, S.; Searcey, M.; Ingelman-Sundberg, M.; Patterson, Laurence H.; Pors, Klaus
Probing cytochrome P450-mediated activation with a truncated azinomycin analogue 2015 MedChemComm 6 187 - 191 Vinader, Victoria; Sadiq, Maria; Sutherland, Mark H.; Huang, M.Y.; Loadman, Paul M.; Elsalem, Lina M.I.; Shnyder, Steven D.; Cui, H.J.; Afarinkia, Kamyar; Searcey, M.; Patterson, Laurence H.; Pors, Klaus
Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging 2013 Djidja, M-C.; Francese, S.; Claude, E.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Cooper, Patricia A.; Patterson, Laurence H.; Carolan, V.A.; Clench, M.R.
Study of the chemotactic response of multicellular spheroids in a microfluidic device 2015 Ayuso, J.M.; Basheer, Haneen A.; Monge, R.; Sánchez-Álvarez, P.; Doblare, M.; Shnyder, Steven D.; Vinader, Victoria; Afarinkia, Kamyar; Fernandez, L.J.; Ochoa, I.
PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma 2016 Ross, R.L.; McPherson, H.R.; Kettlewell, L.; Shnyder, Steven D.; Hurst, C.D.; Alder, O.; Knowles, M.A.
The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models 2016 Scientific Reports 6 31136 Hussain, Nosheen; Connah, David; Ugail, Hassan; Cooper, Patricia A.; Falconer, Robert A.; Patterson, Laurence H.; Shnyder, Steven D. 10.1038/srep31136
Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration 2013 PLoS ONE 8 e73366 Al-Saraireh, Yousef M.J.; Sutherland, Mark H.; Springett, Bradley R.; Freiberger, F.; Ribeiro Morais, Goreti; Loadman, Paul M.; Errington, R.J.; Smith, P.J.; Fukuda, M.; Gerardy-Schahn, R.; Patterson, Laurence H.; Shnyder, Steven D.; Falconer, Robert A. 10.1371/journal.pone.0073366
Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity 2014 Molecular Cancer Therapeutics 11 1294 - 1300 Gill, Jason H.; Loadman, Paul M.; Shnyder, Steven D.; Cooper, Patricia A.; Atkinson, Jennifer M.; Ribeiro Morais, Goreti; Patterson, Laurence H.; Falconer, Robert A. 10.1021/mp400760b
Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA 2015 Rapid Communications In Mass Spectrometry 29 1288 - 1296 Batubara, A.; Carolan, V.A.; Loadman, Paul M.; Sutton, Chris W.; Shnyder, Steven D.; Clench, M.R.
The Effect of Polysialic Acid Expression on Glioma Cell Nano-mechanics 2016 BioNanoScience 6 81 - 84 Grant, Colin A.; Twigg, Peter C.; Saeed, Rida F.; Lawson, G.; Falconer, Robert A.; Shnyder, Steven D. 10.1007/s12668-016-0192-2
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins 2013 Travica, S.; Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Johansson, I.; Alandas, Mohammed N.; Sheldrake, Helen M.; Mkrtchian, S.; Patterson, Laurence H.; Ingelman-Sundberg, M.
Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer 2009 Tomlinson, D.C.; Lamont, F.R.; Shnyder, Steven D.; Knowles, M.A.
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder 2013 Sutherland, Mark H.; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, M.; Pors, Klaus; Shnyder, Steven D.; Patterson, Laurence H.
The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo 2011 Burns, C.J.; Fantino, E.; Powell, A.K.; Shnyder, Steven D.; Cooper, Patricia A.; Nelson, S.; Christophi, C.; Malcontenti-Wilson, C.; Dubljevic, V.; Harte, M.F.; Joffe, M.; Phillips, I.D.; Segal, D.; Wilks, A.F.; Smith, G.D.
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo 2011 Lamont, F.R.; Tomlinson, D.C.; Cooper, Patricia A.; Shnyder, Steven D.; Chester, J.D.; Knowles, M.A.
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer 2013 Herrera-Abreu, M.T.; Pearson, A.; Campbell, J.; Shnyder, Steven D.; Knowles, M.A.; Ashworth, A.; Turner, N.C.
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity 2011 Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark H.; Sheldrake, Helen M.; Guino, M.; Kiakos, K.; Hartley, J.A.; Searcey, M.; Patterson, Laurence H.
Development of a novel tumor-targeted vascular disrupting agent activated by Membrane-type Matrix Metalloproteinases (MT-MMPs) 2010 Atkinson, Jennifer M.; Falconer, Robert A.; Edwards, D.R.; Pennington, C.J.; Siller, Catherine S.; Shnyder, Steven D.; Bibby, Michael C.; Patterson, Laurence H.; Loadman, Paul M.; Gill, Jason H.
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenograft. 2009 Williams, K.J.; Albertella, M.R.; Fitzpatrick, B.; Loadman, Paul M.; Shnyder, Steven D.; Chinje, E.C.; Telfer, B.A.; Dunk, C.R.; Harris, P.A.; Stratford, I.J.
Guaianolide sesquiterpenes from Pulicaria crispa (Forssk.) Oliv. 2008 Phytochemistry 69 1915 - 1918 Stavri, M.; Matthew, K.T.; Gordon, Andrew; Shnyder, Steven D.; Falconer, Robert A.; Gibbons, S.
Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent. 2004 Wilkinson, Gary P.; Taylor, James P.; Shnyder, Steven D.; Loadman, Paul M.; Cooper, Patricia A.; Howard, P.W.; Thurston, D.E.; Jenkins, Terence C.
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. 2007 Shnyder, Steven D.; Cooper, Patricia A.; Millington, Nicola J.; Pettit, G.R.; Bibby, Michael C.
A cytotoxic diterpenoid from Croton membranaceus, the major constituent of anticancer herbal formulations in Ghana 2008 Bayor, M.T.; Ayim, J.S.K.; Marston, G.; Phillips, Roger M.; Shnyder, Steven D.; Wheelhouse, Richard T.; Wright, Colin W.
Synthesis of DNA-Directed Pyrrolidinyl and Piperidinyl Confined Alkylating Chloroalkylaminoanthraquinones: Potential for Development of Tumor-Selective N-Oxides 2006 Patterson, Laurence H.; Pors, Klaus; Shnyder, Steven D.; Teesdale-Spittle, P.H.; Hartley, J.A.; Searcey, M.; Zloh, M.
Pharmacological and biological evaluation of a series of substituted 1,4 naphthoquinone bioreductive drugs. 2004 Phillips, Roger M.; Loadman, Paul M.; Maitland, Derek J.; Shnyder, Steven D.; Jaffar, M.; Steans, Gillian; Cooper, Patricia A.; Race, Amanda D.; Patterson, A.V.; Stratford, I.J.
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. 2005 Wright, Colin W.; Onyeibor, O.; Phillips, Roger M.; Shnyder, Steven D.; Croft, S.L.; Dodson, Hilary I.
Heparin octasaccharides inhibit angiogenesis in vivo. 2005 Hasan, J.; Shnyder, Steven D.; Clamp, A.R.; McGown, A.T.; Bicknell, R.; Presta, M.; Bibby, Michael C.; Double, John A.; Craig, S.; Leeming, D.; Stevenson, K.; Gallagher, J.T.; Jayson, G.C.
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. 2009 Shnyder, Steven D.; Jubb, E.; Hasan, J.; Cooper, Patricia A.; Bibby, Michael C.; Jayson, G.C.; Pilarinou, E.


Dr. Steven Shnyder has 4 publication(s) listed under reviews.
Title Year Publication name Journal Volume Pages Authors Editors ISSN Publisher DOI Location
Non-invasive molecular imaging for preclinical cancer therapeutic development 2013 British Journal of Pharmacology 169 719 - 735 O'Farrell A.;Shnyder S.;Marston G.;Coletta P.;Gill J. 0007-1188 10.1111/bph.12155
RGD-binding integrins in head and neck cancers 2017 Cancers 9 Ahmedah H.;Patterson L.;Shnyder S.;Sheldrake H. 2072-6694 10.3390/cancers9060056
RGD-binding integrins in prostate cancer: Expression patterns and therapeutic prospects against bone metastasis 2012 Cancers 4 1106 - 1145 Sutherland M.;Gordon A.;Shnyder S.;Patterson L.;Sheldrake H. 2072-6694 10.3390/cancers4041106
Quantitative angiogenesis assays in vivo - A review 2004 Angiogenesis 7 1 - 16 Hasan J.;Shnyder S.;Bibby M.;Double J.;Bicknel R.;Jayson G. 0969-6970 10.1023/B:AGEN.0000037338.51851.d1